TY - JOUR
T1 - Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms
T2 - Association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid
AU - Brilakis, Emmanouil S.
AU - Berger, Peter B.
AU - Ballman, Karla V.
AU - Rozen, Rima
PY - 2003/6/1
Y1 - 2003/6/1
N2 - We analyzed the association between the methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms with serum homocysteine and with coronary artery disease (CAD) in 504 patients undergoing clinically-indicated angiography between July 1998 and January 1999. Significant CAD (≥50% stenosis in ≥one artery, blinded to risk factors) was present in 271 patients (54%). Median homocysteine (μmol/l) was 8.8 (interquartile range: 7.5-10.7). The prevalence of the MTHFR TT, CT, and CC genotypes was 11, 44 and 45%, respectively. Median tHcy (with interquartile ranges) for the entire population was 8.8 (7.5-10.7), and for the TT, CT, and CC genotypes was 9.7 (8.2-11.4), 8.8 (7.5-10.7), and 8.6 (7.3-10.6) μmol/l, respectively (P=0.04). On multiple logistic regression analysis, the MTHFR TT genotype was associated with hyperhomocysteinemia (adjusted OR=3.57; 95% CI, 1.47-8.70), but not with significant CAD. The prevalence of the MTRR AA, AG, GG genotypes was 19, 50 and 31%, respectively. There were no differences in mean homocysteine, prevalence of hyperhomocysteinemia and significant CAD between the three genotypes. On multivariate analysis, the MTRR genotypes were not associated with serum homocysteine or with significant CAD.
AB - We analyzed the association between the methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms with serum homocysteine and with coronary artery disease (CAD) in 504 patients undergoing clinically-indicated angiography between July 1998 and January 1999. Significant CAD (≥50% stenosis in ≥one artery, blinded to risk factors) was present in 271 patients (54%). Median homocysteine (μmol/l) was 8.8 (interquartile range: 7.5-10.7). The prevalence of the MTHFR TT, CT, and CC genotypes was 11, 44 and 45%, respectively. Median tHcy (with interquartile ranges) for the entire population was 8.8 (7.5-10.7), and for the TT, CT, and CC genotypes was 9.7 (8.2-11.4), 8.8 (7.5-10.7), and 8.6 (7.3-10.6) μmol/l, respectively (P=0.04). On multiple logistic regression analysis, the MTHFR TT genotype was associated with hyperhomocysteinemia (adjusted OR=3.57; 95% CI, 1.47-8.70), but not with significant CAD. The prevalence of the MTRR AA, AG, GG genotypes was 19, 50 and 31%, respectively. There were no differences in mean homocysteine, prevalence of hyperhomocysteinemia and significant CAD between the three genotypes. On multivariate analysis, the MTRR genotypes were not associated with serum homocysteine or with significant CAD.
KW - Coronary artery disease
KW - Gene polymorphism
KW - Homocysteine
KW - Methionine synthase reductase
KW - Methylenetetrahydrofolate reductase
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=0037497943&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037497943&partnerID=8YFLogxK
U2 - 10.1016/S0021-9150(03)00098-4
DO - 10.1016/S0021-9150(03)00098-4
M3 - Article
C2 - 12801615
AN - SCOPUS:0037497943
SN - 0021-9150
VL - 168
SP - 315
EP - 322
JO - Atherosclerosis
JF - Atherosclerosis
IS - 2
ER -